KC-0107

Ba/F3 BCR-ABL-T315I Cell Line

×
Please enable JavaScript in your browser to complete this form.
19843
Home » 细胞系 » Ba/F3 BCR-ABL-T315I Cell Line

Background of Ba/F3 BCR-ABL-T315I Cell Line

BCR-ABL, breakpoint cluster region–Abelson murine leukemia viral oncogene homolog 1, is an abnormal protein mostly found in chronic myelogenous leukemia (CML) due to the fusion of abnormal configuration of DNA where the abl gene is fused to the BCR gene (The Philadelphia chromosome); BCR-ABL and its mutants can promote and maintain the malignant behavior of the cancer cells. The identification of BCR-ABL as a driver gene has led to the rapid development of anticancer therapeutics agents, including Imatinib, Dasatinib, Ponatinib and Nilotinib. Ba/F3 cell, a murine interleukin-3 dependent pro-B cell line, is a popular system for exploring both kinases and their inhibitors, because some protein kinases can render the Ba/F3 cells to be depended on the activation of the kinases instead of IL-3 supplement, while their inhibitors can antagonize the kinase-dependent growth effects.

Specifications

Catalog NumberKC-0107
Cell Line NameBa/F3 BCR-ABL-T315I Cell Line
Host Cell LineBa/F3
DescriptionStable Ba/F3 clone expressing exogenous BCR-ABL gene bearing T315I point mutation
QuantityTwo vials of frozen cells (≥2-106/vial)
StabilityStable in culture over a minimum of 10 passages
ApplicationDrug screening and biological assays
Freezing Medium70% RPMI1640+20% FBS+10% DMSO
Propagation MediumRPMI1640+10%FBS
Selection MarkerPuromycin
MorphologyMostly single, round (some polymorph) cells in suspension
SubcultureSplit saturated culture 1:10 every 3 days; seed out at about 1-3 × 105 cells/mL
Incubation37 °C with 5% CO2
StorageLiquid nitrogen immediately upon receiving
Doubling TimeApproximately 20 hours
Mycoplasma StatusNegative
In Vivo ValidationNA

Cell Line Generation

Ba/F3 BCR-ABL-T315I cell Line was generated using retrovirus vector expressing BCR-ABL-T315I sequence.

Characterization

Cell Resuscitation

1. Prewarm culture medium (RPMI1640 supplemented with 10% FBS)in a 37°C water bath. 2. Thaw the frozen vial in a 37°C water bath for 1-2 minutes. 3. Transfer the vial into biosafety cabinet, and wipe the surface with 70% ethanol. 4. Unscrew the top of the vial and transfer the cell suspension gently into a sterile centrifuge tube containing 9.0mL complete culture medium. 5. Spin at ~ 125 × g for 5-7 minutes at room temperature, and discard the supernatant without disturbing the pellet. 6. Resuspend cell pellet with the appropriate volume of complete medium and transfer the cell suspension into a T25 culture flask. 7. Incubate the flask at 37°C, 5% CO2 incubator. 8. Split saturated culture 1:10 every 3 days; seed out at about 1-3 × 105 cells/mL.

Cell Freezing

1. Prepare the freezing medium (70% RPMI-1640 + 20% FBS + 10% DMSO) fresh immediately before use. 2. Keep the freezing medium on ice and label cryovials. 3. Transfer cells to a sterile, conical centrifuge tube, and count the cells. 4. Centrifuge the cells at 250×g for 5 minutes at room temperature and carefully aspirate off the medium. 5. Resuspend the cells at a density of at least 3×106 cells/mL in chilled freezing medium. 6. Aliquot 1 mL of the cell suspension into each cryovial. 7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer. 8. Transfer vials to liquid nitrogen for long-term storage.

References

1. Weisberg, E., Manley, P. W., Cowan-Jacob, S. W., Hochhaus, A. & Griffin, J. D. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 7, 345ÿ356 (2007). 2. Akahane, D., Tauchi, T., Okabe, S., Nunoda, K. & Ohyashiki, K. Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: In vitro and in vivostudies. Cancer Science 99, 1251ÿ1257 (2008).
Please enable JavaScript in your browser to complete this form.